CRX-526

CRX-526 is a TLR4 antagonist that can block the interaction of lipopolysaccharide (LPS, HY-D1056) with the immune system, including preventing the expression of pro-inflammatory genes stimulated by LPS, as well as blocking the release of TNF-α induced by LPS. CRX-526 exhibits anti-inflammatory effects in two mouse models of colitis (namely, the dextran sodium sulfate-induced colitis model and the multidrug resistance gene 1a-deficient mouse model) [1].

Product Specifications

CAS Number

[245515-64-4]

UNSPSC

12352005

Target

Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/crx-526.html

Smiles

O=C([C@H](CO[C@@H]1O[C@@H]([C@H]([C@@H]([C@H]1NC(C[C@@H](CCCCCCCCCCC)OC(CCCCC)=O)=O)OC(C[C@@H](CCCCCCCCCCC)OC(CCCCC)=O)=O)OP(O)(O)=O)CO)NC(C[C@@H](CCCCCCCCCCC)OC(CCCCC)=O)=O)O

Molecular Formula

C69H127N2O19P

Molecular Weight

1319.72

References & Citations

[1]Fort MM, et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol. 2005 May 15;174 (10) :6416-23.